EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Effect of Carcinoembryonic Antigen-related Cell Adhesion Molecule-binding Recombinant Polypeptide on the Killing of Neisseria meningitidis by Human Neutrophils

Abdel-Rahman Youssef

Journal of Umm Al-Qura University for Medical Sciences · 2021

DOI: 10.54940/ms10183116 ↗
AbstractBibliografische Angaben

Abstract

Background: Neutrophils are an essential part of innate immunity and play a crucial role in controlling infection caused by Neisseria meningitidis. The Moraxella catarrhalis ubiquitous surface protein A1 (UspA1)-based recombinant polypeptide binds to the carcinoembryonic antigen-related cellular adhesion molecule (CEACAM) 1 receptor on host cells and blocks binding of the mucosal pathogens to human epithelial cells and T cells. Aim of the study: Since the CEACAM1 receptor is expressed on neutrophils, the aim of this study was to investigate the effect of CEACAM1-binding recombinant polypeptide on the ability of neutrophils to kill Neisseria meningitidis. Methods: The effect of CEACAM1-binding recombinant polypeptide on the phagocytic killing of Neisseria meningitidis by neutrophils was assessed by incubation of neutrophils with CEACAM1-binding recombinant polypeptide (UspA1 527–665) or with CEACAM1-non-binding polypeptide control (UspA1 659–863) for one hour before infection with Neisseria meningitidis. The surviving bacteria were released and counted. Results: 30 minutes after infection of neutrophils with Neisseria meningitidis, the survival of bacteria in presence of CEACAM1-binding recombinant polypeptide was 64% compared to 52% with control peptide and 43% without peptide. However, one-hour after infection, the surviving bacteria was 32% in presence of CEACAM1-binding recombinant polypeptide compared to 18% with control peptide and 22% without peptides. Conclusion: Although CEACAM1-binding polypeptide reduced the killing of Neisseria meningitidis by neutrophils, it did not entirely stop phagocytosis and killing of bacteria.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →